ClariVest Asset Management’s Impax Laboratories, Inc. IPXL Stock Holding History

ClariVest Asset Management’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-63,349	Closed	-$839K	–	782
2016 Q4	$839K	Sell	63,349 -62	-0.1%	-$1.06K	0.02%	358
2016 Q3	$1.5M	Hold	63,411	–	–	0.04%	250
2016 Q2	$1.83M	Buy	+63,411	New	+$2.07M	0.05%	221

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

ClariVest Asset Management's IPXL Position: Q1 2017 in Review

ClariVest Asset Management sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 63,349 shares — an estimated $839K sold.

ClariVest Asset Management first reported a position in IPXL in Q2 2016 and held it in 3 quarters. The position peaked at $1.83M in Q2 2016. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

ClariVest Asset Management reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
ClariVest Asset Management sold 63,349 Impax Laboratories, Inc. shares in Q1 2017, an estimated $839K.
ClariVest Asset Management first reported a position in Impax Laboratories, Inc. in Q2 2016 and held it in 3 quarters.
ClariVest Asset Management's Impax Laboratories, Inc. position peaked at $1.83M in Q2 2016.
178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on ClariVest Asset Management's 13F filing for Q1 2017, filed 11 May 2017.